Explore

Trendline Trendline
Otsuka's VOYXACT Shows Promise in Preserving Kidney Function in IgA Nephropathy

Otsuka's VOYXACT Shows Promise in Preserving Kidney Function in IgA Nephropathy

Otsuka's VOYXACT Shows Promise in Preserving Kidney Function in IgA Nephropathy
Trendline Trendline
Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Risks in Lupus Nephritis Patients

Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Risks in Lupus Nephritis Patients

Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Risks in Lupus Nephritis Patients
Trendline Trendline
Aurinia Pharmaceuticals Reports Significant Risk Reduction with LUPKYNIS in Lupus Nephritis

Aurinia Pharmaceuticals Reports Significant Risk Reduction with LUPKYNIS in Lupus Nephritis

Aurinia Pharmaceuticals Reports Significant Risk Reduction with LUPKYNIS in Lupus Nephritis
Trendline Trendline
Ionis Pharmaceuticals to Present New Data on Olezarsen for Severe Hypertriglyceridemia at Major Conferences

Ionis Pharmaceuticals to Present New Data on Olezarsen for Severe Hypertriglyceridemia at Major Conferences

Ionis Pharmaceuticals to Present New Data on Olezarsen for Severe Hypertriglyceridemia at Major Conferences
Trendline Trendline
Fulcrum Therapeutics Halts Development of Sickle Cell Drug Pociredir Amid Safety Concerns

Fulcrum Therapeutics Halts Development of Sickle Cell Drug Pociredir Amid Safety Concerns

Fulcrum Therapeutics Halts Development of Sickle Cell Drug Pociredir Amid Safety Concerns
Trendline Trendline
Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Event Risk by 53% in Lupus Nephritis Patients

Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Event Risk by 53% in Lupus Nephritis Patients

Aurinia Pharmaceuticals Reports LUPKYNIS Reduces Renal-Related Event Risk by 53% in Lupus Nephritis Patients
Trendline Trendline
Clinical Trials Face Recruitment Challenges, Impacting Drug Development

Clinical Trials Face Recruitment Challenges, Impacting Drug Development

Clinical Trials Face Recruitment Challenges, Impacting Drug Development
Trendline Trendline
Satsuma Pharmaceuticals to Present Migraine Treatment Findings at AHS Meeting

Satsuma Pharmaceuticals to Present Migraine Treatment Findings at AHS Meeting

Satsuma Pharmaceuticals to Present Migraine Treatment Findings at AHS Meeting
Rapid Read Rapid Read
Clinical Trials Face Major Recruitment Challenges, Impacting Drug Development

Clinical Trials Face Major Recruitment Challenges, Impacting Drug Development

Clinical trials are experiencing significant recruitment challenges, with approximately 80% failing to meet their enrolment timelines. This issue is largely due to a lack of engagement and education among potential participants, particularly in marginalized communities. The delay in recruitment not only postpones the availability of new treatments but also incurs substantial financial losses for sponsors. The industry has made strides in improving trial processes, such as protocol design and decentralized monitoring, but recruitment remains a bottleneck. The integration of AI is seen as a potential solution to streamline recruitment by identifying and engaging eligible patients more effectively.
Rapid Read Rapid Read
Taiho Oncology Publishes Results of All-Oral Regimen for AML in NEJM

Taiho Oncology Publishes Results of All-Oral Regimen for AML in NEJM

Taiho Oncology has announced the publication of results from the ASCERTAIN-V Phase 1/2 clinical trial in the New England Journal of Medicine. The trial evaluated an all-oral regimen of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy. The study demonstrated favorable response rates and survival outcomes, with a safety profile consistent with existing treatment regimens. This all-oral approach could provide a more convenient and less burdensome treatment option for AML patients who cannot undergo intensive chemotherapy.
Rapid Read Rapid Read
Toregem Biopharma Accelerates Human Trials for Tooth Regeneration

Toregem Biopharma Accelerates Human Trials for Tooth Regeneration

Toregem Biopharma, a Japanese pharmaceutical company, is accelerating its plans for human trials of a tooth regeneration treatment. The company has developed a method to inhibit a gene that suppresses tooth growth, potentially allowing for the regeneration of new teeth. This approach has shown promise in preclinical studies, where it successfully restored teeth in mice. Toregem has raised $5.3 million to support the development of this treatment, with plans to conduct a Phase 2 clinical trial in Japan. The treatment aims to offer a new solution for dental patients, moving beyond traditional options like dentures and implants.
Trendline Trendline
Gilead's Livdelzi Achieves Significant ALP Normalization in PBC Phase 3 Trial

Gilead's Livdelzi Achieves Significant ALP Normalization in PBC Phase 3 Trial

Gilead's Livdelzi Achieves Significant ALP Normalization in PBC Phase 3 Trial